European journal of pain (London, England) · 2026
A Systematic Review With Meta-Analysis of Endogenous Opioid System Biomarkers in Patients With Chronic Axial Pain, Chronic Widespread Pain, and Fibromyalgia.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bruun Karin Due, Moerkeberg Maria Charlotte Reiersoel, Pedersen Julie Roenne, Broholm Daniel, Blichfeldt-Eckhardt Morten Rune, Abildgren Lotte
Аннотация
BACKGROUND: The opioid system is involved in the regulation of pain as well as stress homeostasis. Stress-induced opioid dysregulation has been proposed as a mechanism for pain development in patients with fibromyalgia (FM) and chronic low back pain (cLBP). However, the evidence to support this hypothesis is conflicting.
METHODS: We conducted a systematic literature search in MEDLINE, EMBASE, and the Cochrane Library database to investigate whether patients with FM or cLBP exhibit (1) different levels of endogenous opioids or anti-opioids in body fluids or tissue samples, or (2) altered levels of opioid receptor expression or availability compared to pain-free controls.
RESULTS: We identified 33 studies eligible for inclusion in the review, investigating 863 patients and 636 pain-free controls. Three meta-analyses of beta-endorphin levels in blood and cerebrospinal fluid (CSF) were performed, revealing no significant differences between patients with FM or cLBP and controls. However, the grading of the evidence was very low. Mu-opioid receptor (MOR) dysfunction emerged as a potential feature of FM, with some evidence suggesting reduced MOR binding in the brain and decreased MOR expression in immune cells.
CONCLUSIONS: Current evidence does not support altered peripheral endorphin levels in FM or cLBP, while emerging PET findings indicate reduced central MOR availability in FM. These results suggest receptor-level dysregulation rather than peripheral opioid deficits. Limitations mainly arose from low sample sizes and inadequate study methodologies, underscoring the need for well-designed studies with larger sample sizes to clarify the role of endogenous opioid dysfunction in FM and cLBP.
SIGNIFICANCE: This systematic review highlights emerging evidence of mu-opioid receptor dysfunction in fibromyalgia, despite no consistent differences in beta-endorphin levels. The findings underscore significant methodological limitations in existing studies and point to the need for rigorous, well-powered research to clarify the role of endogenous opioid dysregulation in chronic pain.
METHODS: We conducted a systematic literature search in MEDLINE, EMBASE, and the Cochrane Library database to investigate whether patients with FM or cLBP exhibit (1) different levels of endogenous opioids or anti-opioids in body fluids or tissue samples, or (2) altered levels of opioid receptor expression or availability compared to pain-free controls.
RESULTS: We identified 33 studies eligible for inclusion in the review, investigating 863 patients and 636 pain-free controls. Three meta-analyses of beta-endorphin levels in blood and cerebrospinal fluid (CSF) were performed, revealing no significant differences between patients with FM or cLBP and controls. However, the grading of the evidence was very low. Mu-opioid receptor (MOR) dysfunction emerged as a potential feature of FM, with some evidence suggesting reduced MOR binding in the brain and decreased MOR expression in immune cells.
CONCLUSIONS: Current evidence does not support altered peripheral endorphin levels in FM or cLBP, while emerging PET findings indicate reduced central MOR availability in FM. These results suggest receptor-level dysregulation rather than peripheral opioid deficits. Limitations mainly arose from low sample sizes and inadequate study methodologies, underscoring the need for well-designed studies with larger sample sizes to clarify the role of endogenous opioid dysfunction in FM and cLBP.
SIGNIFICANCE: This systematic review highlights emerging evidence of mu-opioid receptor dysfunction in fibromyalgia, despite no consistent differences in beta-endorphin levels. The findings underscore significant methodological limitations in existing studies and point to the need for rigorous, well-powered research to clarify the role of endogenous opioid dysregulation in chronic pain.